Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
Retrieved on:
Wednesday, January 26, 2022
U.S. Securities and Exchange Commission, Food, Center, Seasonal adjustment, Inflammation, Dry-powder inhaler, European Medicines Agency, Nasdaq, Program, COVID, Pharmacokinetics, COVID-19, Asthma, Intellectual property, HIV disease progression rates, SEC, Therapy, Lung, Death, Risk, Private Securities Litigation Reform Act, BP, Particle size, TMA, COPD, LTB4, Mortality, Thrombotic microangiopathy, Eosinophil, Disease, Leukotriene, Chronic obstructive pulmonary disease, Annual report, Security (finance), Drug development, Leukotriene B4, Regulation of tobacco by the U.S. Food and Drug Administration, CDC, Patient, Degenerative disease, Akari, Eye, EMA, GLOBE, Neutrophil, Korea Disease Control and Prevention Agency, FDA, Failure, Pharmaceutical industry, C5, Zileuton
We are therefore delighted to be working with Inhalation Biosciences AB to further develop an inhaled drug delivery system for nomacopan.
Key Points:
- We are therefore delighted to be working with Inhalation Biosciences AB to further develop an inhaled drug delivery system for nomacopan.
- This points to the potential for nomacopan, a potent inhibitor of both C5 and LTB4, as a focused treatment for disease exacerbations across multiple severe lung disorders, including severe asthma, COPD and COVID-pneumonia.
- Therefore, to optimize the potential clinical utility of nomacopan, Akari is now in development of an inhaled formulation of nomacopan with Inhalation Sciences AB.
- Akari is focused on developing nomacopan for treating exacerbations with a patient-friendly inhaled formulation for early intervention to prevent the potentially serious clinical consequences.